The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study.
OBJECTIVE
A naturalistic, prospective study analyzed the effectiveness of long-acting injectable risperidone (LAIR) in psychotic outpatients.


METHODS
All outpatients (n = 53), affected by Schizophrenia and other Psychotic Disorders, who have begun LAIR at the Mental Health Service of Modena from December 1, 2005 to December 1, 2006, were collected.


METHODS
concomitant oral antipsychotic therapy at the 12th weeks (n = 16 patients) and treatment discontinuation (n = 12). The reasons of drop-out were analyzed. Clinical and demographic characteristics of outpatients (n = 25), motivations, implementation and adverse effects of LAIR treatment were evaluated.


RESULTS
the improvement of symptoms (25% reduction of BPRS and CGI-S scale score from baseline) and functioning level (50% increase of GAF scale score from baseline) at 6th (T6) and 12th (T12) month of LAIR therapy. Secondary outcome: reduction of the hospitalization days during the 1-year LAIR treatment in comparison to the previous year ones of the same patients.


RESULTS
The final BPRS, CGI-S and GAF scores both at T6 and T12 showed a statistically significant difference from baseline (p < 0.0001, t-test). The frequency of improved patients in BPRS, CGI-S and GAF scales were 60%, 68%, 52% at T6, and 72%, 54%, 56% at T12, respectively. Side effects were represented by weight increase (4%), orthostatic hypotension (8%) and EPS (4%). The hospitalization days were statistically significant reduced during the 1-year LAIR treatment in comparison to the previous year ones (p < 0.05, t-test).


CONCLUSIONS
Our data, limited by the small sample and the naturalistic methodology, suggest that 1-year LAIR treatment may be effective and safe.
Di Lorenzo
Rosaria
R
Department of Mental Health, AUSL-MODENA, Servizio Psichiatrico di Diagnosi e Cura 1, Modena, Italy. r.dilorenzo@ausl.mo.it
Fiorini
Fiorenza
F
Santachiara
Sonia
S
D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007267:Injections; D007558:Italy; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D010352:Patient Dropouts; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D018967:Risperidone / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013997:Time Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D018967:Risperidone